Cloudbreak Thereapeutics, founded by ex-Allergan executives, is a clinical stage company focusing on ocular drug research and development. Our lead candidate, CBT-001, is a disease-modifying, first-in-class and first drug therapy to treat pterygium, a common ocular disease. The value proposition of CBT-001 would be developing a "pterygia eye drop" to treat the disease so that patients could avoid surgery, the current standard of care. Cloudbreak has completed Phase II clinical trial in US and had a successful End-of-the-Phase II meeting with the FDA, which enables us to proceed with Phase III clinical trials. We have secured 3 critical patents from USPTO with broad coverage and continued filing additional patent applications with the assistance from Fish & Richardson, our IP legal counsel. As we are currently conducting all necessary non-clinical and CMC studies, we are looking for a strategic partner to conduct global Phase 3 trials, global product registration and commercialization.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):